AZN

AstraZeneca wins two approval recommendations from EU agency

Credit: REUTERS/DADO RUVIC

The European medicines watchdog has recommended approving AstraZeneca Plc's treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday.

Oct 19 (Reuters) - The European medicines watchdog has recommended approving AstraZeneca Plc's AZN.L treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Forxiga for treating a form of heart failure and Trixeo Aerosphere for a form of lung disorder known as "smoker's lung".

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Aditya Soni)

((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More